May 28, 2009
Serametrix Corporation has today launched a new range of serum profiling assays, significantly expanding the current assay offering. Following the success of the Cancer Testis (CT) antigen assay a new range of disease-specific services will comprise the Seromic™ product line. These assays will utilize combinations of disease-specific tumor antigens that are proprietary to Serametrix. The compilation of these antigen collections is the result of in-house research and clinical collaborations with major cancer institutes around the world. Tumor antigens identified by SEREX studies have been combined with known and novel content to produce an exciting new range of assays for melanoma and other cancers including lung, breast, prostate, pancreatic, colorectal and others.
The Seromic™ product line will provide far-reaching opportunities for the discovery of biomarker panels for patient selection, drug target identification, early detection and prediction of adverse effects and other applications in drug development and personalized medicine.